Literature DB >> 8504970

Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.

R D Pullan1, S Ganesh, V Mani, J Morris, B K Evans, G T Williams, J Rhodes.   

Abstract

An enema that contained a complex of bismuth citrate and polyacrylate was compared with 5-aminosalicylic acid (5-ASA) enemas for treatment of distal ulcerative colitis. The multicentre trial involving 63 patients was randomised and double blind with enemas given over four weeks; clinical, sigmoidoscopic, and histological assessments were made. Improvements were seen in both treatment groups. Clinical remission was seen in 18 of 32 patients treated with 5-ASA and 12 of 31 patients treated with bismuth citrate-carbomer (chi 2 1.94; p = 0.16). Sigmoidoscopic remission occurred in 20 of 32 patients in the 5-ASA group and 15 of 31 patients given bismuth (chi 2 1.27; p = 0.26). Improvement of rectal biopsy histology by at least one grade was seen in 16 of 32 patients in the 5-ASA group and 14 of 31 patients with bismuth (chi 2 0.15; p = 0.70). Analysis of covariance gave no significant difference between groups, although there was a trend favouring 5-ASA. There was no evidence of bismuth accumulation during the trial. Bismuth enemas may offer a new therapeutic option in distal ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8504970      PMCID: PMC1374188          DOI: 10.1136/gut.34.5.676

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  Biopsy studies in ulcerative colitis.

Authors:  S C TRUELOVE; W C RICHARDS
Journal:  Br Med J       Date:  1956-06-09

2.  Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea.

Authors:  D A Burke; A T Axon
Journal:  BMJ       Date:  1988-07-09

Review 3.  Bismuth therapy in gastrointestinal diseases.

Authors:  S L Gorbach
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

4.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

5.  Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis.

Authors:  J Powell-Tuck; D W Day; N A Buckell; J Wadsworth; J E Lennard-Jones
Journal:  Dig Dis Sci       Date:  1982-06       Impact factor: 3.199

6.  Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial.

Authors:  M Campieri; R De Franchis; G Bianchi Porro; T Ranzi; G Brunetti; L Barbara
Journal:  Scand J Gastroenterol       Date:  1990-07       Impact factor: 2.423

7.  Mucolysis of the colonic mucus barrier by faecal proteinases: inhibition by interacting polyacrylate.

Authors:  D A Hutton; J P Pearson; A Allen; S N Foster
Journal:  Clin Sci (Lond)       Date:  1990-03       Impact factor: 6.124

8.  Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in colitis.

Authors:  J Powell-Tuck; J E Lennard-Jones; C S May; C G Wilson; J W Paterson
Journal:  Br Med J       Date:  1976-01-24

9.  Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Danish 5-ASA Group.

Authors: 
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199

10.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.

Authors:  L R Sutherland; F Martin; S Greer; M Robinson; N Greenberger; F Saibil; T Martin; J Sparr; E Prokipchuk; L Borgen
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

View more
  15 in total

1.  Meta-analysis of the placebo response in ulcerative colitis.

Authors:  Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily B Levitan; Ciaran P Kelly
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

2.  Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report.

Authors:  K Makiyama; F Takeshima; T Hamamoto
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

3.  A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index.

Authors:  Fumihito Hirai; Toshiyuki Matsui
Journal:  Clin J Gastroenterol       Date:  2008-06-27

4.  Therapeutic role for bismuth compounds in TNBS-induced colitis in the rat.

Authors:  T C Peterson; C E Cleary; A M Shaw; D A Malatjalian; S J Veldhuyzen van Zanten
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

5.  Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

Authors:  Javier P Gisbert; Fernando Gomollón; José Maté; José María Pajares
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

Review 6.  Gastroenterology--II: Small and large bowel, pancreas and biliary system.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  1994-09       Impact factor: 2.401

7.  Colonic mucus, smoking and ulcerative colitis.

Authors:  R D Pullan
Journal:  Ann R Coll Surg Engl       Date:  1996-03       Impact factor: 1.891

8.  Hydrogen sulfide and colonic epithelial metabolism: implications for ulcerative colitis.

Authors:  J Jørgensen; P B Mortensen
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.199

9.  Inhibition of inducible nitric oxide synthase in the human intestinal epithelial cell line, DLD-1, by the inducers of heme oxygenase 1, bismuth salts, heme, and nitric oxide donors.

Authors:  M Cavicchi; L Gibbs; B J Whittle
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

10.  Site of bismuth absorption from bismuth subsalicylate: implications for treatment of colonic conditions.

Authors:  F L Suarez; J Furne; J Stiehm; C Garten; M D Levitt
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.